Dr. McCormack is presently Principal of RMCC, LLC, and is currently consulting for a number of companies in liquid biopsy testing. He is a member of the FNIH Cancer Steering Committee and co-leads its efforts to develop well-validated Quality Control material for ctDNA testing, and was previously a member of the National Academy of Medicine’s Roundtable for Genomic Testing. He has thirty years of invitro diagnostics experience in clinical, regulatory, medical and scientific affairs, and R&D leadership positions at academic institutions, small biotech and large diagnostic companies, and in the pharmaceutical sector. While at Johnson &Johnson, he was a founding member and General Manager of Veridex, LLC, Cellular Technologies, which helped define the liquid biopsy space, Head of Biomarker Strategy for the Disease Interception Group in Janssen Pharmaceutical R&D, and Vice President of Clinical Affairs for Ortho-Clinical Diagnostics. Dr. McCormack received his BS degree from the University of Wisconsin, River Falls, and his MS and PhD degrees from the University of Minnesota.